Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 11/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | FLT3 | P36888 | 4/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | BUB1B | O60566 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | STK25 | O00506 | 1/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12784190 | 0.88 | CCNA2 (0.54) | CCNA2CDK2BRD4IGF1R | |
| SCHEMBL12785200 | 0.82 | CCNA2 (0.62) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL2071643 | 0.80 | CDK2 (0.41) | CCNA2CDK2JAK2FLT3RET | |
| SCHEMBL15827559 | 0.80 | CCNA2 (0.46) | CCNA2CDK2IGF1REGFRNTRK1 | |
| SCHEMBL1163996 | 0.73 | CCNA2 (0.64) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL12785159 | 0.72 | CCNA2 (0.61) | CCNA2CDK2IGF1RDAPK3STK17B | |
| SCHEMBL12783907 | 0.72 | CCNA2 (0.65) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL12784349 | 0.72 | CCNA2 (0.60) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL1164082 | 0.72 | CCNA2 (0.60) | CCNA2CDK2IGF1RDAPK3STK17B | |
| SCHEMBL1164760 | 0.72 | CCNA2 (0.60) | CCNA2CDK2IGF1RDAPK3STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2464641-B1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMA (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885BRD4 258/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885BRD4 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.